The Midwest hospital system aims to embed genetic testing into everyday care for heart disease and discover new genetic risk ...

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...

The agency said the move could halve the time it takes for biosimilars to enter the market, drive competition, and reduce ...

Based on its Q3 performance, the firm raised its full-year sales and EPS guidance and is now expecting sales to be between ...

DMT will use the proceeds to support Phase III development of the gene therapy in wet AMD and diabetic macular edema.

The influential oncology guidelines body revised guidelines with a nod to the FDA's explicit recommendation for testing in Xeloda's label.

The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

The hospital system is betting the move will give it better control over turnaround time and allow it to be more "nimble" in ...

This year, BMS partnered to develop a PD-L1 and VEGF bispecific antibody and has acquired the rights to a new radiopharmaceutical asset.

The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.

The firm is betting that treatments from new acquisitions, including its recent $12B bid for Avidity Biosciences, will ...

Novartis will acquire the firm's neuroscience assets. Meanwhile, Avidity will separate and transfer its precision cardiology programs to a subsidiary.